LifeMD (LFMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
Filing relates to LifeMD, Inc. and includes information for soliciting shareholder votes.
Voting matters and shareholder proposals
Proxy materials are intended to solicit votes from shareholders on matters to be presented at the meeting.
Shareholder rights and capital structure
Filing includes payment of filing fee information and compliance with SEC proxy rules.
Partial view of Summaries dataset, powered by Quartr API
Latest events from LifeMD
- Record revenue growth, expanding margins, and strong cash position drive 2026 outlook.LFMD
Q4 20259 Mar 2026 - Telehealth revenue rose 67% year-over-year, driving profitability and strong margin expansion.LFMDQ2 20242 Feb 2026
- Q3 revenue up 38% to $53.4M, telehealth up 65%, gross margin 91%, and strong cash flow.LFMDQ3 20242 Feb 2026
- Record revenue and EBITDA growth in 2024 set the stage for robust 2025 expansion.LFMDQ4 202426 Jan 2026
- Up to $150M in securities, including $53.3M at-the-market stock, to fund growth and operations.LFMDRegistration Filing16 Dec 2025
- Resale of 1.28M shares highlights Medifast partnership and strong telehealth growth.LFMDRegistration Filing16 Dec 2025
- Telehealth firm launches $150M shelf registration, including $53.3M at-the-market equity offering.LFMDRegistration Filing16 Dec 2025
- Shareholders will vote on director elections and auditor ratification at a virtual annual meeting.LFMDProxy Filing1 Dec 2025
- First-ever GAAP profit and 49% revenue growth drive raised 2025 outlook and telehealth expansion.LFMDQ1 202524 Nov 2025